On February 18, 2025, the CAIMed Scientific Advisory Board was constituted in Hanover. The international advisory board, consisting of renowned experts from AI research, medicine and the biopharmaceutical industry, will provide strategic support to the CAIMed consortium over the coming years. CAIMed has set itself the goal of developing advanced AI methods for clinical decision-making and personalized medicine. With the establishment of the Scientific Advisory Board, CAIMed will receive valuable international support for the transfer of promising AI solutions into clinical application.
Under the leadership of CAIMed Supervisory Board Chairman Dr. Georg Schütte, the board met for the first time and elected Prof. Dr. Niels Peek (University of Cambridge) as its spokesperson. The Board of Directors, led by Prof. Dr. Wolfgang Nejdl, then presented CAIMed's mission, the research portfolio with the clusters AI & Causality, AI & Clinical Decision Support, AI & Active Pharmaceutical Agents and AI & Signals as well as promising use cases for translation.
The newly elected members of the Scientific Advisory Board are:
- Prof. Dr. Dagmar Iber (ETH Zurich)
- Prof. Dr. Manolis Koubarakis (National and Kapodistrian University of Athens)
- Dr. Maren Lang (BioNTech AG Mainz)
- Prof. Dr. Niels Peek – Spokesperson – (University of Cambridge)
- Prof. Dr. Mor Peleg (University of Haifa)
- Prof. Dr. Catia Pesquita (University of Lisbon)
- Prof. Dr. Oscar-Werner Reif (Sartorius AG Göttingen)
- Prof. Dr. Anna Vilanova (Eindhoven University of Technology)
